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Purpose/Objective: Motion management is a major challenge 
in abdominal SBRT. We present our study of SBRT for primary 
or secondary liver tumors using intrafraction motion review 
(IMR) which allows simultaneous KV information and /MV 
delivery to synchronize the beam during gated RapidArc 
treatment. 
Materials and Methods: Between May 2012 and April 2014, 25 
consecutive patients were treated with curative-intent liver 
SBRT. All patients were treated using gated RapidArc 
technique with a Varian Novalis Truebeam STx linear 
accelerator. An isotropic margin of 5mm around the ITV was 
used to create the PTV. Mean PTV volume was 117.81 cc. 
Dose prescription ranged from 40 to 50 Gy in 5 to 10 
fractions. The prescribed dose and number of fractions were 
chosen depending on hepatic function, irradiated liver 
volume and dose-volume histograms results. All patients were 
analysed for toxicity. Twenty-three patients with a minimal 
follow-up of six months were analysed for local control. 
Results: With a median follow-up of 10 months, the 
treatment was well tolerated and no patient presented RILD, 
perforation or gastrointestinal bleeding. Acute toxicity 
consisted on 3 patients with G1 abdominal pain, 1 with G1 
nausea, 8 with G1 asthenia and 1 with G2 asthenia.  
In-field local control was 91.3%, with 5 complete responses 
(21.7 %), 9 partial responses (39.1 %) and 7 stabilizations 
(30.4 %). 2 patients evolved 'in field'. 3 patients had an 
intrahepatic progression 'out of field'. 
Conclusions: The clinical tolerance and oncological outcomes 
were favorable when using Image-guided liver SBRT with real-
time adaptive tumor gating. 
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Purpose/Objective: Radiotherapy induced xerostomia (RIX) is 
the most common permanent side effect of radiotherapy (RT) 
to the head and neck (H&N) with no effective treatment.  
LMS-611 is a mimetic of a natural lamellar body which has 
been shown to have the potential to reduce the ‘stickiness’ 
of oral cavity secretions following RT. 
Our pre-clinical study was designed as an ex vivo, efficacy, 
proof of concept study as a preparatory step towards our 
clinical study of LMS-611 in RIX. 
Materials and Methods: Patients with H&N cancer who were 
booked for RT or chemoRT (CRT) as primary treatment were 
recruited.  
Patient reported xerostomia scores were collected using the 
Groningen RIX (GRIX) questionnaire at baseline, weeks 2, 4 
and 6 of radiotherapy. Saliva samples were also collected and 
adhesiveness and viscosity tested by assessing time taken to 
travel 5cm on an inclined plane (IP). LMS-611 was added to 
saliva samples and IP test repeated. 
Results: 30 patients were enrolled. All patients had a 
pathologically confirmed diagnosis of squamous cell 
carcinoma (SCC) oropharynx. Mean age 54.8 years, range 42-
67. 80% were male and the majority stage III and IV disease 
(96.6%). 90% received CRT. 
The mean IP test results (seconds) are as follows baseline 
31.3; week 2 49.7; week 4 51.1; week 6 55.7 indicating 
increasing saliva adhesiveness and viscosity as RT progresses. 
The increase was significant from baseline to week 2 with 
only moderate increases from week 2 to 4 and week 4 to 6. 
Wide inter-patient variability was seen at baseline. 
GRIX scores increased as RT progressed, see figure. 
Differences between GRIX scores at weeks 2, 4 and 6 were 
statistically significant when compared with pre-treatment 
scores. Modest variability in GRIX scores was seen at baseline 
and this remained constant. 
 
 
The IP test results were compared with GRIX scores, 
Spearman Correlation Co-efficient was -0.06 at baseline, 0.25 
at week 2, 0.12 at week 4 and 0.08 at week 6, therefore no 
relevant correlation was seen. 
The addition of saline, LMS-611 2.5mg/ml or 5mg/ml to the 
saliva samples does not reduce saliva adhesiveness and 
viscosity. However, when LMS-611 in concentrations of 
10mg/ml and 20mg/ml are added a significant reduction is 
seen in the IP test (not shown). Analysing the inclined plane 
results as survival data separately for each time point and 
overall adjusting for week of RT demonstrates this 
statistically significant difference see table.  
 
 
